# **REPORT** 

1 



## **TABLE OF CONTENTS** 

|**Our impact at a glance**|**4**|
|---|---|
|**About Breast Cancer UK**|**5-6**|
|**Welcome from our Chair and Chief Executive**|**7-10**|
|Our Science Programme|11-19|
|Our Education Programme|20-24|
|Our Generous Supporters|25-31|
|Our Advocacy Programme|32-35|
|Financial Review|36-40|
|Structure, Government and Management|42-44|
|**Statement of Trustees Responsibilities**|**45**|
|Independent Auditor’s Report|46-50|
|**Accounts**|**51-63**|



2 



**WE ARE CHANGE MAKERS. WE INSPIRE PEOPLE TO ACT.** 


**----- Start of picture text -----**<br>
3<br>**----- End of picture text -----**<br>




## **OUR YEAR AT A GLANCE** 

## **2024-2025** 


**£2,099,167** (37% increase on last year) **20,000+** Raised for breast cancer Individuals successfully prevention reached across 5 regions 

## **50** 

Talks across the country Raised for breast cancer and online prevention 

**Education and research £548,424.61** Invested in active scientific research projects 


Scientific projects Universities funded **5** (working with) 

**5** 

**Prevention Quiz 10,823** Quiz takers **3,756** Prevention planners 

## **Health & wellness** 

## **Community engagement** 

**12** 

**102** 

**36** 

Podcast episodes made Resources produced (Flyers, blogs, reviews, videos etc) 

Recipes (Including reels) 

**1,494** 

Fundraising pages created **24%** Growth in social media following FY24 year end vs FY25 year end 

**24%** 

4 

Overview 

Science & Education 

Financial review Advocacy & Governance 

Fundraising 

Accounts 



## **ABOUT** 

## **BREAST CANCER UK** 

## **“** 

In the UK, around 56,000 women and 400 men hear the words ‘you have breast cancer’ every year. It is estimated that 1 in 7 mothers, grandmothers, aunts, sisters and daughters will develop the disease at some point in their lives. While not all breast cancers can be avoided, studies show that at least 30% of breast cancer cases are linked to modifiable risk factors. 

**We are the only UK charity driving and advocating for a focus on the primary prevention of breast cancer. ”** 

## **This knowledge** 

is what drives our work and our commitment to change the outlook by tackling this devastating disease head-on. 


**----- Start of picture text -----**<br>
5<br>Financial review<br>Advocacy & Governance Accounts<br>**----- End of picture text -----**<br>


We believe that everyone in society should be able to do something about breast cancer before it happens. Because we know that in doing so, there’ll be less suffering caused by the disease, countless lives will be saved, and we will save over £2 billion in costs to the UK economy, health and community services. 

## **We are change-makers** 

because we focus on understanding and highlighting not just the lifestyle risk factors of the disease, but those which stem from our environment and everyday products. We give practical advice on how people can reduce their risk of getting breast cancer by making simple changes in their lives. A unique aspect of our work focuses on the role played by Endocrine Disrupting Chemicals (EDCs) in increasing the risk of breast cancer and we work with other organisations to make our voice heard on this issue. 

We also fund research that we believe could be a game-changer in the field of breast cancer prevention. 

Overview Science & Education 

Fundraising 



## Our mission 

## **MAKE BREAST CANCER PREVENTION A REALITY.** 

**is to lead a movement to empower individuals, advance scientific research, and reshape policy to reduce breast cancer risk for all. We believe our work can have a significant impact on helping women and men reduce their risk of developing breast cancer.** 

## Our vision 

**is a world where everyone is empowered to reduce their breast cancer risk.** 

## Our values 

**are evidence-based, honest, collaborative, innovative and inclusive.** 

6 

Overview 

Science Financial review & Education Fundraising Advocacy & Governance Accounts 



## **A WORD OF THANKS FROM THE CHAIR AND CEO** 

## **We are delighted to share our Impact Report and Accounts for the financial year 2024/25.** 

This year we witnessed a significant shift in public awareness of our cause, our brand and our life-saving breast cancer prevention work. This was the fruit of our continued effort, together with our generous supporters, to grow our income and expand our work to make breast cancer prevention a reality. 

We want to extend our huge gratitude to our incredible supporters who joined us in growing numbers, lending their voices and fundraising to help us achieve our highest ever income of £2,099,167, a 37% growth on last year. 

Their support has been invaluable in helping advance our work, enabling us to deliver high-impact education to over 20,000 people and fund new cutting-edge scientific research. We thank all of our generous donors and supporters. 

We were thrilled to be able to fund two new scientific research projects this year; a Foundation Award investigating the links between bisphenol exposure, obesity and breast cancer, and a Seed Award investigating the effects of phthalates and parabens on normal breast tissue. This brought the number of scientific research projects we are currently supporting to six, worth a total investment of £568,424.61. 


**----- Start of picture text -----**<br>
7<br>Financial review<br>Advocacy & Governance Accounts<br>**----- End of picture text -----**<br>


Overview 

Science & Education 

Fundraising 



We expanded our education programme through the delivery of over 50 talks to community and staff groups across the country, new accessible content, videos and the launch of our ‘The B Well Podcast’ - speaking to inspirational guests and experts with valuable risk-reducing advice. We worked with our public engagement panel, made up of volunteer members of the public, to ensure that all of our education content is engaging and relevant for the general public. 

We refreshed and strengthened our branding to better reflect who we are and what we do well, and we launched our very first Breast Cancer Prevention Manifesto, setting out what we believe are the policy and partnership priorities for breast cancer prevention to happen. 

This year brought us to the end of our three-year strategy 2022 to 2025, which prompted us to reflect on our achievements and set the direction for the next three years. We worked collaboratively with our supporters, our colleagues and partner organisations to produce a bold new strategy which focusses the next three years on greater growth and a powerful goal to build a world where everyone is empowered to reduce their breast cancer risk. 

Our talented and committed people are why we continue to go from strength to strength. Our board of trustees represented and promoted our charity with passion and commitment, ensuring high quality governance of our work and showed generosity in sharing their time, expertise and insights. We thank our trustees for their unwavering commitment. 

Our dedicated and highly skilled team of colleagues were instrumental in delivering our successful programme of work. Our efforts to cultivate a strong and inclusive work culture and the clarity of our mission have enabled us to attract a diversity of talent and experience, ensuring we can deliver the highest of quality. We thank all of our colleagues for their brilliant effort and commitment. 

**20K £2.1M** 

people who have received education and awarenessraising information **50** 

our highest ever income 

**37%** 

talks to community and staff groups across the country 

growth on income vs last year 

8 

Overview 

Science & Education 

Financial review & Governance 

Fundraising 

Accounts 

Advocacy 



## **A WORD OF THANKS FROM THE CHAIR AND CEO** 

While our achievements bring us a sense of great hope, we know that breast cancer continues to devastate lives and with incidence rates continuing to rise, our work is far from done. We therefore remain laserfocused on our commitment to tackle this disease through effective and lifesaving work that places prevention at the core of the public health and environmental responses to this devasting disease. Together with our supporters and partners we will continue to strengthen our unwavering efforts to make tackling preventable breast cancers a priority. 

## **Ruth Freeborough Chair** 


## **Thalie Martini CEO** 



**----- Start of picture text -----**<br>
16 December 2025<br>**----- End of picture text -----**<br>



**----- Start of picture text -----**<br>
Overview Science<br>& Education Fundraising<br>**----- End of picture text -----**<br>


9 

Financial review & Governance 

Accounts 

Advocacy 



## **STUDIES TELL US THAT AT LEAST 30% OF BREAST CANCERS ARE PREVENTABLE.** 

10 

Overview 

Science & Education 

Financial review & Governance 

Fundraising 

Accounts 

Advocacy 



## **OUR SCIENCE PROGRAMME** 

## **OUR IMPACT AT A GLANCE** 

**We have participated in collaboration with other charities on 4 events and webinars on subjects including forever chemicals and our health, and the environment.** 

**Publications supported by our funding this year:** 



Breast cancer risk and prevention in 2024: An overview from the Breast Cancer UK - Breast Cancer Prevention Conference. Stordal B., Harvie M., Antoniou M.N., Bellingham M., Chan D.S.M., Darbre P., Karlsson O., Kortenkamp A., Magee P., Mandriota S., Silva E., Turner J.E., Vandenberg L.N., Evans D.G. (2024) Cancer Medicine, 13(18):e70255. https://doi.org/10.1002/cam4.70255. 

Low dose effects of environmental chemicals: Bisphenol A as a case study. Encyclopaedia of Toxicology (Fourth Edition), Academic Press, Pages 955-967. Powell C., Mesnage R., Antoniou M. N., Vandenberg L. - - N. (2024). ISBN 9780323854344, https://doi.org/10.1016/B978 0 - - - 12 824315 2.00762 4. 

## **“** 


**----- Start of picture text -----**<br>
Your donations are accelerating knowledge by funding high-<br>quality, animal-free research into underfunded environmental<br>risk factors like EDCs. We ensure these scientific reviews<br>translate into trustworthy public information by embedding<br>expert review and the public’s perspective directly into all our<br>work.<br>”<br>11<br>Science<br>Overview & Education Fundraising Advocacy Financial review& Governance Accounts<br>**----- End of picture text -----**<br>




## **DRIVING CREDIBILITY AND ELEVATING STANDARDS** 

This year, we strengthened our scientific communication and impact. We performed a significant update of our public fact sheets, focusing on the latest research across key areas like lifestyle (diet, exercise), environmental exposures (including PFAS, bisphenols, and parabens), and every life stage from pregnancy through to menopause. 

**To reinforce this, we authored and published four new comprehensive peer-reviewed scientific reviews on critical topics such as phthalates, the microbiome, parabens, and weight, all in relation to breast cancer.** 


## **Independent Scientific Review Panel** 

Our Independent Scientific Review Panel was significantly strengthened this year with the recruitment of five new expert academics. This purposeful rotation brings unparalleled expertise in key areas— including cell biology, toxicology, exercise medicine, and chemistry— guaranteeing fresh ideas and comprehensive perspectives for the critical review of our in-house scientific reports and grants programme. 


## **Public Engagement Panel (PEP)** 

In Autumn 2024, we launched our Public Engagement Panel (PEP). This panel of diverse volunteer members—including those with lived experience of breast cancer—regularly reviews our scientific content. The PEP is vital for ensuring we communicate complex science in the most accessible and appropriate format, embedding the public perspective directly into our charity’s work. 


## **Digital Object Identifiers (DOIs)** 


## **Association of Medical Research Charities (AMRC)** 

This year we began tracking the impact of our work using Digital Object Identifiers (DOIs), allowing us to see exactly where our reviews and grants are cited in wider literature. 

We were awarded Introductory membership to the well-respected Association of Medical Research Charities (AMRC). This reinforces our commitment to excellence. We will submit for full membership in December 2025. 

12 

Science Overview & Education Fundraising 

Financial review & Governance 

Accounts 

Advocacy 



## **BREAST CANCER UK’S GRANT FUNDING PROGRAMME** 

## CURRENT PROJECTS 

- Evaluating the effects of BPA on breast cancer development, University of Aberdeen, Prof Valerie Speirs. 

- Biomonitoring and molecular toxicity profiling of bisphenol mixtures, King's College London, Prof Michael Antoniou. 

- Investigating the carcinogenic and epigenetic modulating effects of per- and poly-fluoroalkyl substances (PFAS) on breast cancer development, University of Hull, Dr Mark Wade. 

- The influence of phthalates and parabens on normal breast tissue and their role in breast cancer risk, University of Manchester, Dr Hannah Harrison. 

- Bisphenols and breast cancer risk: Unravelling the role of adipose tissue, University of Leeds, Dr Giorgia Cioccoloni. 






13 

Science Overview & Education Fundraising 

Financial review & Governance 

Accounts 

Advocacy 



## **PROJECT SNAPSHOTS** 

## **Institute:** 

**Researcher:** 


Lucie Bilton, PhD student **Principal Investigator:** Dr Mark Wade 

## **Project:** 

## **January 2024 - Present** 

Investigating the carcinogenic and epigenetic modulating effects of perand poly-fluoroalkyl substances (PFAS) on breast cancer development. 

## **Project Overview:** 


This project focuses on two areas of concern with regards to chemical exposure: microplastics (tiny pieces of plastic that can contain and release several environmental chemicals) and the forever chemicals PFAS, which are often found in and released from microplastics. 

The project will assess whether PFAS play a role in breast cancer development using human breast cells, and analyse breast tissue samples taken from patients to see if microplastics are present. This would indicate that there is potential for chemicals such as PFAS to be released into the breast tissue itself, which could contribute to an increased breast cancer risk. 

## **Progress so far:** 

Normal breast cells have been exposed to human-relevant concentrations of PFAS chemicals for short and long exposure periods. The effects of these exposures are now being analysed to see whether changes occur immediately or develop over a longer period. Experiments are currently ongoing and include looking at whether exposure to PFAS increases cell growth, affects DNA and whether structures that resemble those found in the normal breast are altered. 

14 

Science Overview & Education 

Financial review & Governance Accounts 

Fundraising 

Advocacy 



## **PROJECT SNAPSHOTS CONT.** 

**Researcher:** 

## **Institute:** 

Arya Pilani, PhD student **Principal Investigator:** Dr Giorgia Cioccoloni 


## **Project:** 

**November 2024 - Present** 

Bisphenols and breast cancer risk: Unravelling the role of adipose tissue. 

## **Project Overview:** 


This project aims to enhance the understanding of the relationship between bisphenol exposure, obesity, and breast cancer. Bisphenols are Endocrine Disrupting Chemicals (EDCs) that are attracted to and have been found in human fat tissue. 

There is some evidence that certain chemicals, such as bisphenols, may contribute to weight gain and obesity, which is a risk factor for postmenopausal breast cancer. 

The project will investigate how breast cells change after they encounter fat cells that have been exposed to bisphenols, before examining exactly how these changes happen and whether they could drive breast cancer onset. The research hopes to find better ways to prevent breast cancer by shedding light on how these chemicals affect our health. 

## **Progress so far:** 

This is a relatively new project with progress so far including; the start of an in-depth review of current literature on how bisphenol compounds and obesity impact human health. This will help with understanding the current level of knowledge in this area and whether any gaps exist that could be filled. Lab work so far has included identifying the optimal conditions and number of cells required for planned experiments. These will involve exposing fat cells to bisphenol compounds for short and long periods of time and analysing their effects. 

15 

Science & Education 

Financial review & Governance Accounts 

Overview 

Fundraising 

Advocacy 



## **ELEVATING IMPACT: A NEW ERA FOR OUR GRANT PROGRAMME** 

We remain dedicated to funding high-quality, animal-free research focused on understanding breast cancer causes and risk factors, particularly in the underfunded area of environment-associated risks and Endocrine Disrupting Chemicals (EDCs). 

**To maximise our strategic impact and support researchers at every critical stage, we have evolved our funding into two distinct streams: the Foundation Award and the Seed Award.** 

|**Award**<br>**Key Feature**<br>**Purpose & Impact**<br>**Amount**|**Award**<br>**Key Feature**<br>**Purpose & Impact**<br>**Amount**|**Award**<br>**Key Feature**<br>**Purpose & Impact**<br>**Amount**|**Award**<br>**Key Feature**<br>**Purpose & Impact**<br>**Amount**|
|---|---|---|---|
|Foundation Award|To anchor promising early<br>career scientists, enabling<br>them to establish their<br>own independent research<br>programme focused on<br>chemicals and breast<br>cancer prevention.|Includes a career<br>coaching programme to<br>support the new<br>investigator for the<br>grant’s duration.|Up to<br>£150,000|
|Seed Award|A small, flexible grant<br>designed for immediate<br>needs: topping up near-<br>complete projects,<br>purchasing essential<br>equipment, or funding a<br>crucial pilot project on<br>chemicals and breast<br>cancer risk.|Provides flexible funding<br>to accelerate focused,<br>high-priority research<br>objectives.|Up to<br>£25,000|



## Rigorous Standards and Inaugural Success 

To ensure we fund only the highest calibre work, every application undergoes a rigorous process, including peer review by at least two experts from our Independent Scientific Review Panel. Final funding decisions are made by the Science and Public Affairs Committee. 

16 

Science Overview & Education 

Financial review Advocacy & Governance 

Fundraising 

Accounts 



**This year, we were thrilled to award our firstever Foundation and Seed Awards:** 

**Foundation Awardee:** 

**Dr. Giorgia Cioccoloni** (University of Leeds). Her research aims to enhance the understanding of how bisphenol exposure interacts with obesity to influence breast cancer risk, paving the way for better prevention strategies. 

## **Seed Awardee:** 

**Dr. Hannah Harrison** (University of Manchester). Her work uses novel laboratory models to investigate the effects of common chemicals like phthalates and parabens on normal breast tissue, adding vital evidence to the field and helping us address EDC use in everyday products. 

## Growth and Collaboration 

**The revised structure has been exceptionally well-received.** Our autumn 2024 grant round, featuring both awards, attracted 100% more applications year-on-year—a testament to the urgent need for this type of funding. Final decisions for this highly competitive round will be announced in early summer 2025. 

Additionally, we introduced our inaugural Grant Holders Meeting this year, inviting all awardees (including research assistants and PhD students) to share their project overviews. The feedback was overwhelmingly positive; this knowledge-sharing and support platform will now become an essential annual meeting to foster collaboration and excellence across our research community. 

**“** Just to say how much I enjoyed the online event BCUK organised yesterday. Thank you for doing this. It was great to bring together the people you fund, especially the students, and find out what’s going on… I hope you will consider an event like this again or some other type of online activity for them, as it gives students a sense of belonging to a cohort 

**”** 

17 

Science Overview & Education Fundraising 

Financial review & Governance Accounts 

Advocacy 




## **ELEVATING IMPACT: A NEW ERA FOR OUR GRANT PROGRAMME** 

The expansion of our science program is already underway, with our most recent grant round launching new funding streams dedicated to cultivating the next generation of breast cancer researchers. 

To ensure this growth is strategic and sustainable, we are developing a dynamic 2025–2028 Science Strategy. This forward-thinking approach will detail how we plan to expand our grants programme sustainably and identify new, crucial areas of health information for our community. 

In June 2025, we will be hosting our second Breast Cancer UK Prevention Conference at Middlesex University. We have already secured a variety of excellent speakers, including Dr Barbara Cohn, Director of the Child Health and Development Studies in Berkeley, California, as well as Professor Marc Gunter from Imperial College London and Dr Jennifer Kay from the Silent Spring Institute, Massachusetts. 

We are looking forward to hearing the fantastic research that is contributing to furthering our understanding of the causes of breast cancer, and the event promises to deliver a brilliant learning and networking opportunity for all in attendance. 

18 

Science Overview & Education Fundraising 

Financial review & Governance 

Accounts 

Advocacy 



## **ARE YOU READY TO BE THE FORCE FOR CHANGE? JOIN THE MOVEMENT TODAY.** 


**----- Start of picture text -----**<br>
19<br>**----- End of picture text -----**<br>


Science Overview & Education Fundraising 

Financial review & Governance 

Accounts 

Advocacy 



## **OUR EDUCATION PROGRAMME** 

## **OUR IMPACT AT A GLANCE** 


**----- Start of picture text -----**<br>
Prevention Quiz Educational talks Taking action<br>20K 50+  85%<br>people talks of attendees<br>delivered to<br>took up our reported feeling more<br>prevention message community groups motivated to take<br>this year. and corporate action to reduce their<br>partners. risk.<br>**----- End of picture text -----**<br>


## Every donation directly fuels our mission to shift the conversation from treatment to prevention, saving lives before they are at risk. 

## **OUR PROACTIVE EDUCATION PROGRAMME: A PATH TO PREVENTION.** 

While medical advances in breast cancer treatment are vital, we know that a significant number of cases are linked to preventable risk factors. For many people, the path to prevention is unclear. They lack access to trusted, evidence-based information and feel disempowered to act. 

That’s why we are passionate about producing accessible, science-backed educational resources. Our supporters have consistently told us that our educational content is a valuable source of trusted information—a fact we're proud to say is validated by our PIF (Patient Information Forum) tick accreditation. 

20 

Science Overview & Education Fundraising 

Financial review Advocacy & Governance 

Accounts 





## **INTERACTIVE QUIZ** 

## **EMAIL JOURNEYS** 

We're proud to offer our interactive quiz as the starting point for a personal prevention journey. Once individuals have identified their risk and the lifestyle areas they want to improve, they can access a range of free resources to help them make meaningful changes. 

To support sustained change, we have created tailored 5-month email journeys that guide our supporters to develop new, healthy habits. At the end of the journey, they can retake the quiz to see how far they've come and celebrate their progress towards a healthier future. 

**10,823 1,789** People took the People signed up to the prevention quiz healthy habit email journeys **3,756 81%** People signed up for People reported changes their action plan in their behaviour 

21 

Science Overview & Education 

Financial review & Governance 

Fundraising 

Accounts 

Advocacy 



## **SPOTLIGHT SUCCESS** 

## **FROM APATHY TO ACTION, OUR TALKS TRANSFORM LIVES.** 

This year, we partnered with a number of companies and businesses to deliver talks to their employees. These sessions, delivered all over the country in person and remotely, focused on practical steps for a healthier lifestyle, resulting in over 300 employees taking our Prevention Quiz and providing overwhelmingly positive feedback. 

## **ENGAGING NEW AUDIENCES: EMBRACING THE DIGITAL REVOLUTION IN PREVENTION** 

This past year, we successfully launched The B Well Club Podcast, a new digital initiative focused on wellness backed by science. The first season of 10 episodes serves as a critical tool for preventative education, targeting women over 30 who seek to build healthy lifestyles. 

This demonstrates the power of our programme to empower individuals and create a ripple effect of health and awareness within major organisations. We are proud that our talks help raise awareness and champion the notion that everyone can do something to help reduce their breast cancer risk. 

“Really informative, succinct and useful information I wasn’t aware of. The talk was framed in a positive way, which I find more motivational.” 

Each episode features an expert discussion topic that contributes to breast cancer risk reduction, from breastfeeding and physical activity to reducing exposure to harmful chemicals. The podcast’s success lies in its ability to empower women with accessible, actionable advice, directly supporting our mission to help them live a happy, healthy, long life and reduce their risk of breast cancer. This initiative represents a significant step in our educational outreach. 

The podcast was downloaded over 800 times in its first season, with episodes on topics like alcohol and exercise proving the most popular. By launching the B Well Podcast, we are meeting our audience where they are, providing accessible, engaging content that supports long-term behaviour change. This digital platform provides a scalable and sustainable model for future growth. 

22 

Science Overview & Education 

Financial review & Governance 

Fundraising 

Accounts 

Advocacy 



## **SPOTLIGHT SUCCESS: A NEW CHAPTER FOR OUR EDUCATION PROGRAMME** 

Our new education strategy is complete, and we have a clear direction for the next three years. We're not just continuing our work; we're launching a dynamic, focused, and forward-looking programme designed to reach a wider audience than ever before. We are incredibly excited to deliver this ambitious plan in the upcoming financial year. 

## **WHAT'S ON THE HORIZON:** 

A brand-new education library: We're building a comprehensive library of resources to make our educational content more accessible and engaging. 


## **Accessible online education:** 

our new online resources will be developed with accessibility in mind, ensuring everyone can benefit from our life-saving information. 


## **Tailored talks and content:** 

streamlining our talks and articles to better serve our diverse community and deliver our messaging in a more impactful way. 


## **The Youth Project:** 

a major part of our strategy is understanding how to connect with and empower a younger audience, and our new Youth Project will lead the way. 

## **Join us in building the future of prevention** 

**To achieve these goals, we're seeking partners who share our vision. Your support is more than just a donation; it's a powerful statement of your commitment to proactive health and a future where preventable breast cancer is a thing of the past. Together, we can build a world where education empowers everyone. Are you ready to join us and help make this future a reality?** 

23 

Science Overview & Education Fundraising 

Financial review Advocacy & Governance 

Accounts 



## **LET’S CHANGE THE NARRATIVE AND TURN THE TIDE AGAINST BREAST CANCER.** 


**----- Start of picture text -----**<br>
24<br>Science<br>Overview & Education Fundraising Advocacy Financial review& Governance Accounts<br>**----- End of picture text -----**<br>




## **OUR GENEROUS SUPPORTERS** 

## **OUR IMPACT AT A GLANCE** 

**New fundraising pages created** 

**1,494** 

**Increase in income vs last year 37%** 




**New regular givers** 

**866** 

**In-memory donations 2,528 received** 

> **Total legacyincome £889,155** 

Thank you to all of our wonderful supporters for your commitment and incredible generosity. The funds raised support our ground-breaking research into the environmental factors that contribute to breast cancer. 

## **POWERING PREVENTION, ONE DONATION AT A TIME.** 

Our committed supporter base continues to amaze us with their generous support. This year, we have continued our steady income growth. This allows us to reach more people with our educational prevention resources and to fund vital animal-free scientific research into the causes of breast cancer, so that we can understand how we can prevent more cases and protect future generations from the devastating impact of a diagnosis. We want to send our heartfelt thanks to all of our supporters. It not only means a lot but your support is what makes everything we do possible. 

25 

Science Fundraising Overview & Education 

Financial review Advocacy & Governance Accounts 



## **SPOTLIGHT SUCCESS** 

## **THE B WELL CLUB** 

Our regular donors 

Introducing **The B Well Club.** Regular mailings that share exclusive content to help our supporters reduce their risk of breast cancer. 

**Exclusive content made:** 

**36+ recipes reels, scientist videos, blogs and more** 

**B Well Club members:** 

**866** 

## **PAUL CUROTTO** 

Fundraiser case study 

In Autumn 2024 a group of four friends decided to cycle the 170-mile Way of the Roses. Despite two tragic losses in the same year - one to breast cancer - two of the friends completed the challenge to raise over 5 times their target for Breast Cancer UK. 

## **Fundraising goal:** £500 

**Fundraising total:** 

£2672 

26 

Fundraising 

Science Overview & Education 

Financial review & Governance 

Accounts 

Advocacy 



## **CORPORATE PARTNERSHIPS** 

Our new, values-led approach to corporate partnerships led to exciting collaborations... 



## **THE REFEREES ASSOCIATION** 

## **BARNSLEY FC** 

Like our partnership with The Referees Association and our orange laces campaign, which helped us reach new audiences with our prevention message. 

Continuing the football theme, Barnsley FC wore our logo on their shirts for a match broadcast on Sky TV. 

## **WANT TO FUNDRAISE OR JOIN US AS A CORPORATE PARTNER?** 

**As we look ahead, we’re seeking to build meaningful collaborations with organisations that share our commitment to positive social impact. Align your brand with a cause that reflects your values and demonstrates your organisation’s commitment to social responsibility. Get in touch with us today!** 

27 

Fundraising 

Science Overview & Education 

Financial review & Governance 

Accounts 

Advocacy 



## **BURBAGE CHARITY BIKES** 

**What started as a "crazy dad idea" during the 2020 lockdown has transformed into a remarkable charity project.** When his daughter Jess's London Marathon was cancelled, Steve Daly began refurbishing unwanted bicycles to raise money for charity. With the help of his family and a team of dedicated volunteers, Steve established Burbage Charity Bikes. 

The project accepts donated bikes of all kinds, refurbishes them, and sells them at affordable prices. Every penny raised is donated to charity. Since its launch, the project has sold around 3,000 bikes and raised over £20,000 for Breast Cancer UK. 

Burbage Charity Bikes has pledged to support Breast Cancer UK, to raise £30,000. The partnership aligns with our shared values of promoting physical activity to improve health. 

**The Daly family and their volunteers give their time and resources for free, embodying a powerful commitment to community and charitable giving. This initiative is a testament to what a simple idea, combined with passion and community support, can achieve. We can’t thank them enough.** 


**----- Start of picture text -----**<br>
Bikes sold Money raised Pledged<br>3000 £20k+ £30k+<br>28<br>Overview & EducationScience  Fundraising Advocacy Financial review& Governance Accounts<br>**----- End of picture text -----**<br>




## **BIRDS & BOOBS** 



It's not just clothing; it's a statement. May marked the exciting launch of our new apparel line, Birds & Boobs. 

The launch created a significant buzz, catching the attention of multiple print and online publications and even gaining a notable feature from the wonderful Sara Cox, who proudly wore one of our T-shirts. Birds and Boobs is about turning a simple idea into a powerful movement for change. Watch this space—the future of fashion for good is here. 

- Developed entirely by our dedicated team with design support from Breezign, our ethically produced, prevention-focused range is designed to be kinder to your skin and better for the planet, while directly funding our breast cancer prevention work. 

Thanks to your incredible support, we sold over £19,828.71 worth of apparel in our first year alone. This success is just the beginning. We're now setting our sights on a bold new goal: building what we hope will become the UK’s leading for-purpose fashion brand. 

£19,828.71 worth of apparel sold in our first year alone 

100% of profits go to breast cancer prevention 

29 

Fundraising 

Science & Education 

Financial review & Governance 

Overview 

Accounts 

Advocacy 



## **FULL SUPPER CLUBS** 

Full is a focus on community and connection. In January, we were thrilled to launch the Full Supper Club, an initiative designed to bring people together around the table. 

The concept is simple yet powerful: hosts invite friends and family to a ticketed supper club in their own home. The proceeds from these events— including ticket sales and any additional donations, go directly towards our vital work in breast cancer prevention. 

This year, we've been focused on empowering individuals to host their own events, but we're already looking to the future. 


To help our hosts create an unforgettable gathering, we've developed an exclusive hosting pack. This fundraising kit is filled with delicious, wholesome recipes, expert hosting tips, and an fun icebreaker game to get conversations flowing. 

## **FULL SUPPER CLUB PACK STATS** 

199 Pack downloads 

14 Chefs included 

## **FUTURE PLANS** 

Our upcoming plans include co-hosting supper clubs with established clubs and partnering with restaurant chains to host their own unique events. We invite you to learn more about hosting your own Full Supper Club and becoming a part of this growing community. 

30 

Fundraising 

Science & Education 

Financial review & Governance 

Overview 

Accounts 

Advocacy 



WE CAN
MAKE A
DIFFERENCE.
vi
Overview
Sci8Thco
& Education
Advocacy
nanea

## **OUR ADVOCACY PROGRAMME** 

## **OUR IMPACT AT A GLANCE** 

Parliamentary champions for our cause 

**2** 


**----- Start of picture text -----**<br>
153 MPs<br>received<br>our<br>manifesto<br>153<br>**----- End of picture text -----**<br>



**----- Start of picture text -----**<br>
People<br>pledging<br>to help<br>ban EDCs<br>3000+<br>**----- End of picture text -----**<br>


**OUR ‘WHY’ STATEMENT:** 

**“ Build a movement that drives the policy change needed to reduce preventable cases of breast cancer. ”** 

## **THE LAUNCH OF OUR MANIFESTO** 


**----- Start of picture text -----**<br>
32<br>Overview & EducationScience  Fundraising Advocacy Financial review& Governance Accounts<br>**----- End of picture text -----**<br>




## **SPOTLIGHT SUCCESS: OUR PREVENTION MANIFESTO:** 

## **How many copies were sent?** 

**We approached the launch in a 2-tier system, tier 1 hard copies and tier 2 digital copies.** 


**----- Start of picture text -----**<br>
Soft (digital) copies<br>64.8%<br>**----- End of picture text -----**<br>



**----- Start of picture text -----**<br>
Hard copies 153<br>35.2%<br>hard copies of the<br>Manifesto were sent<br>in tier 2<br>83<br>**----- End of picture text -----**<br>


**83** hard copies of the Manifesto were sent in tier 1 

**We successfully launched our dynamic manifesto in June 2024 in the lead up to the general election.** This timing represented a real opportunity for us to showcase areas of unmet need across Government with regards to breast cancer prevention. By launching our manifesto after the election this meant strategically, we were able to pour more resources into those newly elected MPs who demonstrated a deeper interest in shared areas of concern. We approached the launch in a 2-tier system, tier 1 being hard copies of the manifesto, of which 83 were sent, and tier 2 including soft copies in a digital format, of which 153 copies were sent. All contacts were followed up, some of which resulted in meetings with MPs. 

This year has also resulted in two Parliamentary Champions for Breast Cancer UK. These are Patrick Hurley (Lab, Southport) and Helen Grant (Con, Maidstone and Malling). This means they have shown dedication in promoting our work through their social media and contact with constituents and also using parliamentary avenues, such as questions and debates, to raise points for us. 


**----- Start of picture text -----**<br>
Science<br>Overview & Education Fundraising<br>**----- End of picture text -----**<br>



**----- Start of picture text -----**<br>
33<br>Advocacy Financial review<br>& Governance Accounts<br>**----- End of picture text -----**<br>




## **MOBILISING SUPPORTERS WHO SHARE OUR MISSION** 

The starting group for the mobilisation work is our ‘EDC Pledgers’. The individuals known as EDC pledgers have pledged to, “urge the UK Government to strengthen public protections to ensure known EDCs are removed from products to safeguard public health and the environment and to support breast cancer prevention.” 


**People pledging to 3000+ help ban EDCs** 

We have maintained communication with this group throughout the year, soliciting feedback on a draft of our manifesto. Over 150 individuals provided submissions and suggestions. 

In addition, our new Public Affairs and Advocacy Strategy is nearing completion, with a planned launch in late spring or summer of 2025. 

## **EXPANDING OUR PARTNERSHIP TO MAGNIFY OUR VOICE** 

We have been a driving force behind the NGO Working Group which brings together several organisations with interests in chemical regulation. A sub-group was formed from this, the ‘Health sub-committee’, which looks specifically at the human health implications of exposure to harmful chemicals. Additionally, we continue to attend meetings of the EDC-Free Europe coalition, helping us to keep up to speed with policy developments in the EU and the UK’s alignment with or divergence from these. We have also stayed in contact with the European Movement, sharing information and ideas around alignment with EU REACH. 

Finally, we joined the One Cancer Voice (OCV) a coalition of UK cancer charities spearheaded by Cancer Research UK working together to drive positive policy change on cancer. Our first joint effort was on our collective call for a National Cancer Plan in which we highlighted the need for effective prevention measures. 

## **FUTURE PLANS** 

**Through our growing partnerships we will ensure the government hears our calls for a National Cancer Plan that has prevention at its core.** 

**Alongside this work we will launch our new Campaigns and Advocacy strategy setting out our objectives for the next three years in which we will build a movement that engages, supports and activates our supporters to empower them to drive breast cancer prevention into meaningful policy.** 

34 

Advocacy 

Science & Education Fundraising 

Financial review & Governance 

Overview 

Accounts 



## **BREAST CANCER WILL AFFECT AROUND 1 IN 7 WOMEN IN THE UK.** 

35 

Advocacy 

Science & Education Fundraising 

Financial review & Governance 

Overview 

Accounts 



## **FINANCIAL REVIEW** 

The Directors present their report with financial statements of the company for the year ended 31st March 2025. In preparing this report the Directors have taken advantage of some of the special exemptions applicable to small companies. 

## **KEY HIGHLIGHTS** 

Legacies were our Our total income Total expenditure highest source **£2,099,167 £889,155 £1,896,868** 

**Previous % Change** £1,537,624 37% 

**Previous % Change** £321,406 177% 

**Target By** Underspent 17% 

## **PRINCIPAL FUNDING SOURCES** 

Total funds raised this year were £2,099,167. This represents a 40% increase against the original budget of £1,494,950. Income this year is 37% more than last year’s total funds raised of £1,537,624. Over the past five years (from FY 20/21 to FY 24/25) income has increased by 213%. Income from legacy, Gift Aid and bank interest also shows overall growth of 556%. 

FY24/25 saw a notable increase in legacy donations which represented the highest source of income at a total of £889,155 (including 3 legacies of more than £100,000) representing 42% of total income and was a 177% increase on FY23/24 where we received £321,406 in legacies. We also received income from In Memory giving of £173,472. Community Fundraising was our next largest source of income (£531,119). 


**----- Start of picture text -----**<br>
Sources of income*<br>**----- End of picture text -----**<br>



**----- Start of picture text -----**<br>
GrantsGift aid<br>Staff fundraising 7.9% 0.5%<br>4.3%<br>Individual Giving<br>6.1%<br>Community fundraising<br>27%<br>In memory giving<br>8.8%<br>Science<br>Overview & Education Fundraising<br>**----- End of picture text -----**<br>



**----- Start of picture text -----**<br>
Legacies<br>45.2%<br>**----- End of picture text -----**<br>



**----- Start of picture text -----**<br>
Fundraising Advocacy<br>**----- End of picture text -----**<br>


36 

Financial review & Governance 

Accounts 



Community Fundraising is made up of Individual Fundraising (£354,759) and fundraising by educational facilities, sports clubs and other clubs/societies (£176,360). 

Whilst the overall income from Community Fundraising is very similar to 23/24, we have seen an ongoing decline in Individual Fundraising, mirroring the general sector trend, but this was offset by an increase in the other Community Fundraising income lines. 

Income from Individual Giving was £120,71, made up of £75,961 from individual7 donations, £9,329 from payroll giving, £35,427 from regular giving and £19,829 from Sale of Apparel. This shows a significant increase in this income stream of £140,546 compared to 23/24 (£93,761), mainly as a result of an increase in Regular Giving and the introduction of our Sales of Apparel. We have significantly increased our investment in both of these areas of work and are expecting to see these income streams continue to grow in future years. 


**----- Start of picture text -----**<br>
Key areas of income<br>400000<br>300000<br>200000<br>100000<br>0<br>Individual FundraisingFundraising by clubs etcIndividual donationsCorporate donationsCause-related marketingRegular giving Sale of apparelSolicited grantsPayroll givingUnsolicited grants<br>**----- End of picture text -----**<br>


We received £84,954 in income from staff fundraising events in companies, £43,602 from corporate donations and £27,919 from cause-related marketing which is a significant increase on the previous year. We continue to partner with smaller companies and individuals too, and would particularly like to thank them for their ongoing support. 

In 24/25 we received a total of £15,545 in solicited grants and £1,250 in unsolicited grants. Apart from these grants, all donations are unsolicited and come from those people affected in some way by breast cancer, who choose to donate or fundraise for our cause. Gift aid continues to be a significant source of income, and we are focusing on maximising gift aid contributions as part of our ongoing fundraising development. 

37 

Financial review & Governance 

Science & Education 

Advocacy 

Fundraising 

Overview 

Accounts 



## **CHARITABLE EXPENDITURE** 

This financial year total expenditure amounted to £1,896,868 reflecting a 17% underspend against the budget of £2,289,684. We continued to manage spending cautiously due to rising concerns relating to the cost-of-living crisis and we review our investments and returns quarter by quarter and assess risk as part of all investment decisions. 

Our continued commitment to invest in our scientific research programme resulted in total expenditure of £169,880. In FY24/25, 80% (£1,525,834) was spent on charitable activities, and 20% (£371,034) on raising funds, compared to 74% and 23% respectively in FY23/24. 


**----- Start of picture text -----**<br>
KEY HIGHLIGHTS<br>80% spent this<br>year vs (74%)<br>Charitable activities £1,525,834<br>FY23/24<br>20% spent this<br>Raising funds £371,034 year vs (23%)<br>FY23/24<br>Total expenditure £1,896,868 17% underspent<br>**----- End of picture text -----**<br>


## **RESERVES POLICY** 

## **PURPOSE OF THE RESERVES** 

The charity holds reserves to provide funding to support the continuation of the charitable aims and objectives and the ability to meet financial commitments in the event of a significant unforeseen reduction in income or increase in operational costs. 

## **LEVEL OF RESERVES** 

The level of reserves is set by considering the uncertain nature of the charity’s income and the recurrent expenditure and financial commitments the charity has. The charity has minimal overheads arising from accommodation as we do not have a central office space (and make use of free accommodation for meetings where we can). Hence our main financial commitments and running costs arise from staffing and research grants. 

## **DESIGNATED FUNDS** 

The charity is committed to funding research into the chemical and environmental causes of breast cancer. Research grant applications from independent academic institutions are considered periodically and approved at the Board level. 

38 Accounts 

Financial review & Advocacy Governance 

Science & Education 

Fundraising 

Overview 



Designated funds represent funds approved by the Board for future spending on research grants and other projects that aim to deliver our charitable objectives. The level of designated funds is updated throughout the year to reflect the amount of funds set aside for future projects until the funds are either committed to a project or a decision is made to un-designate them if a project does not go ahead. 

## **FREE RESERVES** 

Breast Cancer UK is committed to a programme of activity that meets our charitable objectives. Given the uncertain nature of legacies, budgets are prepared on the assumption that only in cases where we have already been formally notified, are they included in income. 

As a result, sudden large legacies or donations that are received during the financial year can result in reserves being held that are more than Breast Cancer UK’s reserves policy (free reserves) after allowing for designated funds. 

To help us address this, we have built into our business plans scenario planning for our research and education projects which allow for scaled up investments to fast track completion of projects or expand outputs. Thus, excess legacies or unexpectedly large donations will be directed promptly to these projects. Having monitored legacy income and engaging with our supporters to better understand their intentions, this year we included projections of legacy giving into our income target setting. 

In addition, we regularly review our investments on our financial investment platform (Flagstone) to ensure we are investing our capital wisely to balance flexibility with achieving the best rate of return on our reserves and other capital. 

## **AUTHORITY, MONITORING AND REPORTING** 

Ongoing monitoring of the reserves is undertaken during the year by the CEO, COO, Finance Manager and Finance Trustee. At the time mid-year financial results and budgets are revisited, the reserves position including how funds are allocated is reported to the Audit, Risk and Resources Committee (ARRC) meeting and the Board. 

## **RESERVE POLICY REVIEW** 

The Reserves Policy is reviewed annually by the ARRC in February/March and approved by the Board of Trustees in March, reviewing in detail the reserve position and taking into account prevailing conditions in the charity sector and short-term and medium-term plans for the charity. 

At the Board meeting of 24th March 2025, Trustees determined that £400,000 should be held in emergency reserve. This represents 3 months of staff and non-staff costs, based on the 25/26 annual budget. 

39 

Financial review & Advocacy Governance 

Science & Education 

Fundraising 

Overview 

Accounts 



General unrestricted funds at year-end were £2,286,379 of which £686,461 were designated funds, including £502,619.87 for science grants and foundation award, £26,783.88 for the Breast Cancer Prevention Conference and £157,056.59 on other charity projects. 

Net of designated funds and our emergency reserve of £400,000 excess free reserves were £1,199,918. We recognise the global financial uncertainty that remains, and were pleased to see that despite this, our income continued to grow throughout the year. However, we maintain a precautionary approach to our charity finances, to ensure we can weather the storm of any financial crisis ahead. 

## **RESULTS AND CLOSING POSITION** 

## **FORECAST SURPLUS/DEFICIT** 

The charity has a surplus of £202,299 for the financial year. Our total income increased by £561,543 from 2024. Our total expenditure was 17% under budget. Total income exceeded our original annual budget target by £604,217. 

This is a significant improvement from the board-approved budget at the start of the year, which projected a deficit of £638,688 and an expected net asset position of £1,091,069. As it stands, the current projected net assets are £2,333,145, signalling a strong financial turnaround. 

|**Metric**<br>**2024/25 Budget**<br>**24/25 actual**<br>**Change vs Budget**|**Metric**<br>**2024/25 Budget**<br>**24/25 actual**<br>**Change vs Budget**|**Metric**<br>**2024/25 Budget**<br>**24/25 actual**<br>**Change vs Budget**|**Metric**<br>**2024/25 Budget**<br>**24/25 actual**<br>**Change vs Budget**|
|---|---|---|---|
|Surplus/deficit<br>Total income<br>Net assests<br>Total expenditure|£202,299 surplus|£638,688 deficit|+£840,987<br>+£1,242,076<br>+£604,217<br>-|
||Up £561,543 from 2024|Exceeded target by<br>£604,217||
||17% under budget|£2,289,684||
||£2,333,145|£1,091,069||



40 

Financial review & Advocacy Governance 

Science Overview & Education 

Fundraising 

Accounts 



## **MAKE BREAST CANCER PREVENTION A REALITY.** 


**----- Start of picture text -----**<br>
41<br>Financial<br>Science  review &<br>Overview & Education Fundraising Advocacy Governance Accounts<br>**----- End of picture text -----**<br>




## **STRUCTURE, GOVERNANCE AND MANAGEMENT** 

## **STRUCTURE** 

Breast Cancer UK is a charitable company limited by guarantee (registration number 07348408), registered on the 8th November 2010 and registered as a charity on the 15th August 2001 (registered charity number 1138866). The company was established under the Memorandum of Association, which established the objects and powers of the charitable company. In the event of the company being wound up, members are required to contribute an amount not exceeding £10. 


**----- Start of picture text -----**<br>
1 2 3<br>to advance health to educate and raise to support scientific<br>and save lives by awareness of the research that helps<br>encouraging a preventable risk us to understand<br>factors for breast<br>preventative and address the<br>cancer and provide<br>approach to breast preventable risk<br>practical information<br>cancer. factors for breast<br>to help people<br>cancer.<br>reduce their risk.<br>**----- End of picture text -----**<br>


## **GOVERNANCE** 

The Directors of the Company, who are listed on the last page of this report, are also charity trustees for the purposes of charity law and under the Company’s articles are known as members of the Board of Trustees. 

All members of the Board of Trustees give their time voluntarily and receive no benefits from the charity. Any expenses reclaimed from the charity are set out in note 3 to the accounts. Several trustees have suffered from breast cancer or are close to people who have suffered from the disease. They use their own experience in this area to assist the charity. 

In recruiting Trustees, the members seek to ensure the charity benefits from a broad range of different skills and expertise including a good understanding of charity governance practice and compliance. Skills and expertise represented on the board include science, research and policy, medicine, governance, finance and accountancy, fundraising, PR, business management and IT. 

42 

Accounts 

Science & Education 

Financial review & Governance 

Advocacy 

Fundraising 

Overview 



In the event of skills or individuals being lost due to retirements or resignations, the charity advertises for Trustee roles and interviews are carried out to ensure the most appropriate appointments are made. 

This year we sadly said farewell to Silvy Mardiguian and Beezy Marsh, who both resigned due to increasing work and personal commitments. We were delighted to welcome two new Trustees to the board, Yvonne Price and Professor Chris Twelves, who each joined the board on the 24th of March 2025. 


**----- Start of picture text -----**<br>
Board of Trustees<br>Science and Fundraising,<br>Audit, Risk and<br>Public Affairs Communications<br>Resources<br>Committee Committee and Campaigns<br>Committee<br>**----- End of picture text -----**<br>


## **STAFF** 

Our colleagues are our greatest asset and in recognition of the value that they bring to our cause, we work hard to build a culture and work place that allows every colleague to thrive in working collaboratively to achieve our common goals. Our efforts to grow our brand and profile has made us more competitive and alongside our positive work culture and attractive benefits package, our efforts to retain staff and attract talent are continuously reviewed with a view to remaining competitive. 

This year we undertook a restructure to our executive team, introducing three new directorates to help steer our ambitious plans. Reporting to the CEO are the Chief Operating Officer, the Director of Research and Engagement and the Director of Fundraising and Communications. We continued to expand our teams to bring greater skills in science, communications and financial management to strengthen our operational team. 


**----- Start of picture text -----**<br>
43<br>Accounts<br>Science  Financial review<br>Overview & Education Fundraising Advocacy & Governance<br>**----- End of picture text -----**<br>




## **RISK MANAGEMENT** 

A risk register is in place and periodically reviewed by the board. Risk management sits with the CEO and ownership sits with specific Committees and the Board. The Committees of the Board of Trustees and the Board itself reviews the Risk Register at each meeting and it is updated regularly. Mitigating actions are considered and reviewed regularly. All policies and processes are under rolling review to ensure we are compliant with regulation. 

## **STATEMENT OF PUBLIC BENEFIT** 

The Trustees confirm that they have complied with the duty in Section 17 of the Charities Act 2011 to have regard to the Charity Commission’s General Guidance on public benefit. 

Our charitable objectives are enshrined in our Memorandum of Association and Trustees to ensure that the charity’s activities are carried out for the public benefit. In July, these articles were formally amended with a special resolution passed to amend our ‘objects’ clause through our three new strategic approaches: 

- **to advance health and save lives by encouraging a preventative approach to breast cancer** 

- **to educate and raise awareness of the preventable risk factors for breast cancer and provide practical information to help people reduce their risk to support scientific research that helps us to understand and address the preventable risk factors for breast cancer.** 

This report allows us to show how our charitable funds are spent and the impact that this has on those that access our information or use our services, as well as on the wider challenge to reduce breast cancer incidence rates. 

By Order of the Board 

## **Ruth Freeborough (Chair and Director of the Board of Trustees) Breast Cancer UK Limited** 


~~1629~~ December 2025 

44 

Accounts 

Science & Education 

Financial review & Governance 

Advocacy 

Fundraising 

Overview 



## **STATEMENT OF TRUSTEES RESPONSIBILITIES** 

## **FOR THE YEAR ENDED 31 MARCH 2025** 

The Trustees (who are also the directors of Breast Cancer UK Limited for the purposes of company law) are responsible for preparing the Report of the Trustees and the financial statements in accordance with applicable law and United Kingdom Accounting Standards (United Kingdom Generally Accepted Accounting Practice). 

Company law requires the trustees to prepare financial statements for each financial year which give a true and fair view of the state of affairs of the charitable company and of the incoming resources and application of resources, including the income and expenditure, of the charitable company for that period. In preparing those financial statements, the trustees are required to 

- select suitable accounting policies and then apply them consistently observe the methods and principles in the Charity SORP 

- make judgements and estimates that are reasonable and prudent prepare the financial statements on the going concern basis unless it is inappropriate to presume that the charitable company will continue in business. 

The trustees are responsible for keeping proper accounting records, which disclose with reasonable accuracy, at any time, the financial position of the charitable company and to enable them to ensure that the financial statements comply with the Companies Act 2006. They are also responsible for safeguarding the assets of the charitable company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities. 

The trustees are responsible for the maintenance and integrity of the corporate and financial information included on the charitable company's website. Legislation in the United Kingdom governing the preparation and dissemination of financial statements may differ from legislation in other jurisdictions. 

45 

Accounts 

Science & Education 

Financial review & Governance 

Advocacy 

Fundraising 

Overview 



## **INDEPENDENT AUDITORʼS REPORT TO THE MEMBERS OF BREAST CANCER UK LIMITED** 

## **OPINION** 

**We have audited the financial statements of Breast Cancer UK Limited (the ‘Charity’) for the year ended 31 March 2025 which comprise the Statement of Financial Activities, the Balance Sheet, statement of cash flows and the related notes. The financial reporting framework that has been applied in their preparation is applicable law and United Kingdom Accounting Standards, including Financial Reporting Standard 102: The Financial Reporting Standard applicable in the UK and Republic of Ireland (United Kingdom Generally Accepted Accounting Practice).** 

## **OPINION ON FINANCIAL STATEMENTS** 

In our opinion the financial statements: 

- give a true and fair view of the state of the charitable company’s affairs as at 31 March 2025 and of its income and expenditure for the year then ended: 

- have been properly prepared in accordance with United Kingdom Generally Accepted Accounting Practice; and 

- have been prepared in accordance with the requirements of the Companies Act 2006. 

## **BASIS FOR OPINION** 

We conducted our audit in accordance with International Standards on Auditing (UK) (ISAs (UK)) and applicable law. Our responsibilities under those standards are further described in the Auditor's responsibilities for the audit of the financial statements section of our report. We are independent of the Charity in accordance with the ethical requirements that are relevant to our audit of the financial statements in the UK, including the FRCʼs Ethical Standard and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion. 

## **CONCLUSIONS RELATING TO GOING CONCERN** 

In auditing the financial statements, we have concluded that the Trustees’ use of the going concern basis of accounting in the preparation of the financial statements is appropriate. 

46 

Accounts 

Science Overview & Education Fundraising 

Financial review & Governance 

Advocacy 



Based on the work we have performed, we have not identified any material uncertainties relating to events or conditions that, individually or collectively, may cast significant doubt on the charity's ability to continue as a going concern for a period of at least twelve months from when the financial statements are authorised for issue. Our responsibilities and the responsibilities of the directors with respect to going concern are described in the relevant sections of this report. 

## **OTHER INFORMATION** 

The Trustees are responsible for the other information. The other information comprises the information included in the annual report other than the financial statements and our Auditor's report thereon. Our opinion on the financial statements does not cover the other information and, except to the extent otherwise explicitly stated in our report, we do not express any form of assurance conclusion thereon. 

In connection with our audit of the financial statements, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the audit or otherwise appears to be materially misstated. If we identify such material inconsistencies or apparent material misstatements, we are required to determine whether there is a material misstatement in the financial statements or a material misstatement of the other information. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact. 

We have nothing to report in this regard. 

## **OPINION ON OTHER MATTER PRESCRIBED BY THE COMPANIES ACT 2006** 

In our opinion, based on the work undertaken in the course of the audit: 

- the information given in the trustees’ report (incorporating the directors’ report) for the financial year for which the financial statements are prepared is consistent with the financial statements; and 

- the trustees’ report (incorporating the directors’ report) has been prepared in accordance with applicable legal requirements. 

## **MATTERS ON WHICH WE ARE REQUIRED TO REPORT BY EXCEPTION** 

In the light of the knowledge and understanding of the Charity and its environment obtained in the course of the audit, we have not identified material misstatements in the Trustees’ Annual Report. 

47 

Accounts 

Science & Education 

Financial review & Governance 

Advocacy 

Fundraising 

Overview 



We have nothing to report in respect of the following matters where the Companies Act 2006 requires us to report to you if, in our opinion: 

- adequate accounting records have not been kept or returns adequate for our audit have not been received from branches not visited by us; or 

- the financial statements are not in agreement with the accounting records and returns; or 

- certain disclosures of Trustees’ remuneration specified by law are not made; or we have not received all the information and explanations we require for our audit. 

## **RESPONSIBILITIES OF THE TRUSTEES** 

As explained more fully in the Trustees’ Responsibilities Statement, the Trustees (who are also the directors of the charitable company for the purposes of company law) are responsible for the preparation of the financial statements and for being satisfied that they give a true and fair view and for such internal control as they determine is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error. 

In preparing the financial statements, the Trustees are responsible for assessing the Charity’s ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the trustees either intend to liquidate the Charity or to cease operations, or have no realistic alternative but to do so. 

## **OUR RESPONSIBILITIES FOR THE AUDIT OF THE FINANCIAL STATEMENTS** 

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an Auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs (UK) will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements. 

Irregularities, including fraud, are instances of non-compliance with laws and regulations. We design procedures in line with our responsibilities, outlined above, to detect material misstatements in respect of irregularities, including fraud. The extent to which our procedures are capable of detecting irregularities, including fraud are set out below. 

48 

Accounts 

Science & Education 

Financial review & Governance 

Advocacy 

Fundraising 

Overview 



In identifying and assessing risks of material misstatement in respect of irregularities, including fraud and non-compliance with laws and regulations, our procedures included the following: 

We enquired of management, which included obtaining and reviewing supporting documentation, concerning the charity's policies and procedures relating to: 

   - Identifying, evaluating, and complying with laws and regulations and whether they were aware of any instances of non-compliance; 

   - Detecting and responding to the risks of fraud and whether they have knowledge of any actual, suspected, or alleged fraud; The internal controls established to mitigate risks related to fraud or noncompliance with laws and regulations. 

- We inspected the minutes of meetings of those charged with governance. We obtained an understanding of the legal and regulatory framework that the charity operates in, focusing on those laws and regulations that had a material effect on the financial statements or that had a fundamental effect on the operations of the charity from our professional and sector experience. We reviewed the financial statement disclosures and tested these to supporting documentation to assess compliance with applicable laws and regulations. We performed analytical procedures to identify any unusual or unexpected relationships that may indicate risks of material misstatement due to fraud. In addressing the risk of fraud through management override of controls, we tested the appropriateness of journal entries and other adjustments, assessed whether the judgements made in making accounting estimates are indicative of a potential bias and tested significant transactions that are unusual or those outside the normal course of business. 

Because of the inherent limitations of an audit, there is a risk that we will not detect all irregularities, including those leading to a material misstatement in the financial statements or non-compliance with regulation. The risk is also greater regarding irregularities occurring due to fraud rather than error, as fraud involves intentional concealment, forgery, collusion, omission or misrepresentation. 

A further description of our responsibilities for the audit of the financial statements is located on the Financial Reporting Council's website at: [www.frc.org.uk/auditorsresponsibilities]. This description forms part of our auditor’s report. 

## **USE OF OUR REPORT** 

This report is made solely to the charitable company’s members, as a body, in accordance with Chapter 3 of Part 16 of the Companies Act 2006. Our audit work has been undertaken so that we might state to the charity’s members those matters we are required to state to them in an auditor’s report and for no other purpose. 

49 

Accounts 

Science & Education 

Financial review & Governance 

Advocacy 

Fundraising 

Overview 



To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the charity and the charity’s members as a body, for our audit work, for this report, or for the opinions we have formed. 


29 December 2025 

## **Anthony Epton (Senior Statutory Auditor)** 

for and on behalf of **Goldwins Limited** Statutory Auditor 

Chartered Accountants 75 Maygrove Road, West Hampstead, London, NW6 2EG 

50 

Accounts 

Science & Education 

Financial review & Governance 

Advocacy 

Fundraising 

Overview 



Fov th•
end4d J l 2025
2025
2024
IlTh*strK*d fttSiikt*d
Fund
Fund fol￿ Fund
Fvthd
fund Tgtal Fwbd
No
Oonabons and It9ac•os
Charitsble ￿tr￿￿*S
In¥*slm*nts
1.994.900
22,J14
81.953
1.9N.9fy) 1.443.859
22.314
41.•53
11,11• 1.464,977
7Z.647
72.617
2.0>9. 167
2,QM.167 1.516.$06
21.118 1.537.624
J71.034
371,OJ4
2>6.631
2J6.631
Fundiwjtng AMr•n•ss
and Edu(ai￿n
Or9anis•iK>n Oov*lopmethi ￿PP￿￿
556.2 33
571.452
395.990
556.233
STJ.611
3•5.•90
176.304
386.637
2 36.857
176.J04
510.219
236,8S7
2.159
123,512
Tatsl •xp•ndll4v•
1.8W,709
2.159 1,••6.868 1.036.429
123.582 1. 160.01
N•t lfvcoN* I ffvxp•fidM¥rt) th•
204.458
Q.159)
201.2
180.077 1102.464}
377.613
Tf*lls1•15 b•knfi Iwnds
N•t Incom* l *xp•mdtrtyrn) b•hv•
o¢hw fffOgDl••d o•ln• 4•d
204.4S8
Q.1591
201.1
480.077 1102.464)
377.61 J
201.458
(2.15•
202.299
480.077 1102.464}
J17,613
A•c¢xxlllaO¢>n ol lunds:
Toul fvndi ￿0¥￿h1 lonwd
2.Nl,921
48.93S 2,IM846 1.601.•44
151.M9 1,753.133
T•thl ¢wfl•d lot¥Jwd
2.216.37•
46.716 2.3J3.145 2.011.921
48.925 2. 1 JO.146
41 atthe lte deii¥ed li(•Tb C(ffiIIWNJ ¥lb%ii•e& Tl*ie wtie Th) ￿0￿r*￿￿ •wns Iw ilw ikne
51
Overview
Science
& Education
Advocacy
Financial raviaw
& Govornanca

•re4$1 Cancw UK Umli•d
•aknnce sheet
As at 31 Mafch 2025
Coryny no. 07348408
2025
2024
Note
Flx•d a51•ts:
Tangible assets
2,103
Curr•nt as$1ts:
Sio(k
Debiors
Cash af bankand In ￿fid
29,843
416,326
21 2.163,J33
191.082
2.251.559
2.609,502
2.442.641
U•blllil•s:
CTedlior5'. amounN falling due wKhin ono yeai 14 11 $6.954)
(185.371)
14•t curimt as5•¢5 1 (lknb11111•5)
1.452,548
2,257.270
T<Aal assets less current lthbllltles
2.454,731
2,257,270
Credlion". amounts filllng due after one year 15
1121.586)
(126.424)
Taoal n•t assets i (Il•bllltloil
2.333.145
2,130,846
Th• funds of th• chafliy.
R￿trIcted iftcomt lunds
Unie5trirted IrKome lunds..
Deslgnaied funds
Genoral funds
19
46,766
48.925
686,461
1.599,918
712.782
1.369.139
Total unre51rlcted lunds
2.286.379
2.081.921
Total funth
2.333,145
2,130,846
The Iinancthl statements been piepared In accoidanct wlth iht speclal provlslons f¢x small
companles undef Partl 5 of ihe Companles Aci 2006,
Appiovtd by ihe liustees ¢>n .
16 December 2025
. and slGned on thelr behall by
rL
Ruth Freebofough
Trustee
52
Overview
Science
& Education
Advocacy
Financial raviaw
& Govornanca

1fv411 C•rK•r VK Llfflft•d
Stslem•nl of cash fknvs
N¢t•
202S
2014
Cash fkn from op•rntlrf
N•t cash Pfovld•d by l (¥i•d In> OP•fatlfio
acttrdlths
20
1167.424)
246.887
In￿$t1￿j actMtI•s
In¥*sirn•ni In¢om• ftc•￿0
81.953
72.647
N•1 cash g•h•rnttd fmm IfN•iilr4 Act￿1￿*1
81,953
72.647
Cash 1kn￿ from In￿%•￿• ￿1￿#1•$.
Purchas* ol Ilxed a5se15
12.7551
N•t cash pftw￿•d by l (¥s•d In> Inv•stlno •clhltl•s
Q,755)
lft ush •nd ush •qul¥•l•rfi In th• y••r
18122•
319.S34
Cash and tash oqulvaknnis li ihe beglnnlno of ih*
v••r
2.251.559
1.9J2.025
C41h ind •q¥*é•l•fiis ai ih •fid of ih y•ar
1.163.33J
2251.S59
53
Overview
Science
& Education
Advocacy
Financial raviaw
& Govornanca

o•si C4A¢ei IM UN￿4
No*5 *1 th•
orth•
ar •nd•d 3 I 11￿￿h
l Acco¥ndng polkks
Ch4tlty thlomwb"
east Can<oi UK knmrttd is a prtyat• company Iimiwd by quaiante* in<orp<¥ai¢d in England and Wal•
The iegisieitd offKe is . CIO Gold￿￿$, 75 Maigwow& Road. London. Enoland. NW6 2EG.
a) lull al pr•pwalbD
Th• financ￿1 st4t•ffl•nii b•+n pitpared In 4¢10rdan¢• with A¢counting al￿ A￿0111￿9 bv
Chaiiiies.. ol Rèc*)mm*nded appliuble io chaiitlos pwèp411fi9 ih*ii K<ounii In
co*d•nce wlth ihe FIA4n¢l&l Repo•1￿4 $14nd¥d •pplk4bl¢ In the UK 4nd IlèpubFl¢ ol liolwbd IFIS 102
•ff•ctiw4 l Januwy 20191 (Chaiibts SORP FAS 1021 CompaTri•s A(12C*)6.
The ch4ilt•blt COMp￿V meets the delinilk>n of • publK benecli enllty ¥ndef FRS IQ2. A55*1s Ind
li•bdikneJ 41* Inlll•lly 1*¢09ni>•d al hlittylul ¢011 ty Ir•ns•cli¢fi v•Juo unhss In th*
i•l•vant 4¢<tyJntlw polky or n•w.
b) Golr4 c¢nc•r
•1 the ieporting date that h•vt 4 5bynihc•nl risk of I•us109 • m•teiwl adwslment * th*
¢•rryinq 4mo•Jnls ol Asset$ and I￿￿1111*$ withbN th• n•xl r•poiiiny p•1￿￿.
Ini4yn* Is i•r¢gnlMd ih• ¢lwvlty h45 •n¥ihrn*fii io th• Iwdl. p•iIrym•￿• ¢+)nd•lloni
4114cbEd to the i￿ornE have meL il Is piobablt Ih•t the income will be re(eThed th•¢ the
Dwii can b* measu1￿ ieli4blv.
lfvtom* fiom gtY4*1nment ind gianis, 'c&pIt￿. gl*b)lJ 01 't•¥+nu•' grAhi*, li V•¢*)gfils•d
Ib•n ch•fity has enliY*m*nt to lh• Iwnds, any p*iloim&ni• cond•tyon$ 4tl4ch•d io th• gr4nts h4
b••n met. li Is wobabl• thai fv kncom• *411 b• i•cw4*d and th• affloufit b• m•asui•d i01￿bI¥ and
Is dtkiied.
For kg&t*i. •niiilpméni Is tak•fi as th* wk*i ol th• d&t• ofi *thl¢h elth*r.' th• <harlfy Is I￿1
piobat• has ￿1n 914Dtsd, th •s¢4¢• has bo•n finalis•d •nd noliflc•tlon b••• m•d• by t
•x*<uiovlsl to th* chaiity thai a disiribution wlll b* m￿•, a distributsofi is i•¢••%*d fiom th•
•ststr. Ileceipt ol a legacy. In oi In pail. li ordy coniid+ied piobabl* the amouni b•
IMaSUfed f*h•bly th• <harity has nolil*d ol ¢xo(ul¢l'5 Intinlion tty mak* a disliibuts4YI.
Wheie le9￿￿$ bten r+ollfied io chaiity. w tho rh•rity 1$ awar• ol the granting ¢>f piobate. and
th* (illet￿ foi ie¢ogDltron hav• Mil m•L ih•n lh• l•ycy li 4 tr••l•d as a contiog*nl
assot and d•s(ltsMd Il mattiial.
Iniomt rQ(•iv￿ in •dw•r*c• ol th• PIV￿51￿￿ of • gp•¢ifi•d sqTric• Is d•f•ll￿ un¢ll th• crlQ•ib• I
lrtcomè ie£ognitJon ai¢ mél.
d) Donallons s•Thb(•s •nd l•tllthi
DoA4ied piolesslon41 servKes and don41od 14cll¢lles ￿09￿lled as lTrcomt T*hen th• ch411ty has
ontrol ovei ihe iiem or iÈYei¥ed the seiv•ce. Condli￿n5 a5￿ClaI•d with ihe don4tlon beon
mti. th• i•c•ipi ol •<ontrmk b•n•lii from th• ui• by lh• C￿lity tsl the it•m •% probabh Ind it￿1
*<ov*omlc bènefii m*4stsied ièlithly. In ac(￿danc* ￿th th* Chliitses SORP IFRS 1021, T•oluntsei
Ilfft? IS Ilot I•C¢Vksed io i•lei ty) lh• tyus1••s' •nftu•b lep￿1 moi• thltyffl•tffj• •bout Ih*lr
th* ¥&lut of th* ¥lft to ihé <￿ilty *thl<h is ihé aNbtsuni chiilty would h4* willkng tts pay to
obtsin S•VVK•S or l•rih¢it• ol qquw•l•vl ocgngmk btrwfil thi m•rk•l.' • iorr•wDdmq
mouni Is ihen iecognisod in Qxpendiwie In t￿ peiiod ol foc•lo.
kn¢•r•si M<•￿bI•
Inleie51 on fuTrJ5 ￿ld on d•pos11 Is Ib¢ltyd•d [K￿y•ble and th* amouni cafft b• m•4s¥i•d i•ll•bly
by ihe ch*rity'. this Is Th>1M￿lY upon fiotlficaiwn of lthe intef•sI p&d oi Payab￿ by Ihe
Q Fur4
Roslricted funds ts> b* used loi sp*clfic purposes as IW by the don¢t. Expen**"tyie ¥thk*4
meets these <iiieii& Is <huged ￿ the fvnd.
iknrtstrxthd Ivnds doMiths rfh*i lfKomthg iesowt¢*s ie¢eoY4d ¥Y geneilted the
fufids Wt wr*stri¢W l¥fids wm&rk4d by the trusi*es l•t partl¢ul*i purp•ses.
54
Overview
Science
& Education
Financial raviaw
& Govornanca
Advocacy

o•si C4A¢ei IM UN￿4
No*5 *1 th•
orth•
•r •nd•d J l M•Kh 20
I kcwnlln9 polkl•J IconlJN•d)
q) EMp•fidilw• ind in•¢4y•*fabl• VAT
Expeodituie Is ieco9fiised onc¢ theie 1$ 4 legal oi <onswucth¥e obh9*￿ ￿ m*ke 4 ￿¥ment w a th*d
rty. li Is piobabl* that s•ttlem•nt *ill be itquiied Wbd the amavnt ol Ihe otslwailon can b• ffl••stsi•d
r*liablw, Expendiluie 15 rlasyfKd ynd¢r the lollowin9 a(tr￿ty head•Thg5-.
Cosls ol fvnds i•lat• to tho (osis od Iy Ih Ihaiitabk company * Ir￿￿￿￿9 thyd
p4vi*% ￿ m•k¢ b•l¥r•￿v (Ontrilwlbpns to *( as w•ll •$ thi ¢osi ol any a¢kniiws a I￿r1dVa••ing
pyipos•
Exp•nditui• <hawitsbl• ac11￿11¢$ ihclud•s lh• cr•sts •1 d•ll%*rlng und•fuk¢n * f¥rth•r
Othei QMponditui• those •i•ms fW)i falllng •nio inv oihei heading
liie(owèi&blè VA T Is chaiged as a COSI all￿￿$1 the a(b¥ity foi *hKh the oxptthdiiuro I￿¥11￿.
11> All•¢allM •f s¥pport ¢osts
R•wui¢•i •Jtp¢nd•d •1• 41kn¢41•d io th* paitl¢ulai •¢litAty wher• ￿91 r*l•l•s dlr•¢ily to i￿1
Imty. Ho￿￿1. the cosi ol 0￿1￿11 diceiti¢Jo and administrabon ol each compli￿Tr4 tht
S•1￿￿ ar*d owih*thl ¢o%is 01 the <•ntt41 fun<bon, i5 4ppoitsoMd on the bail> *thi¢h ai• In *SiimA*,
¥Theit InformaDon aboui the aim& Obp(v￿9 and pro)Kts ol Ihe charlty Is prO￿ded kn PDlonllal
b•n•lKlail•i. th• <oiti lis￿lA1*d wlth this publicrty am allocai*d ts ¢hailt4bh •xp•¢bdiWf•.
l*n141 ch&rg•J 41• ¢hw4•d •n • itr•b4hi IIM b•sli •*1 th4 t•im ol th* I•AM.
Iltms ol *qUbpm¢nl ¢*pi¢•llMd *h¢r* th• pw¢hAw pi*¢¢ •y¢Mds I I.IXrf). O•piff tr•tlofi ¢oii$ 4r•
allocatsd lo icbvives on the basis ol the use ol the rolat•d assets In thoso acts*itles. Assets •1•
i•viewrtd ltsw Imsmiimlrti If Iiicumswic*s IndK•i• th¢•r may •Jrc•od th•ii fv•i1•4i￿bl*
v•bu¢ aDd valw• in us•,
i•sMlual value its •xpKtrd lif•.
OffK* équipmthi
J years Ott • itsalght-llft* b•s1s
k)
St*xk Is in<1￿1*d at lh• ltr*ti ol tost oi h*t r+alis￿le ¥&lut Donaltd itimi of stock &1* i•(0gnvJd al
lalr Y￿￿* 1% th• amtsuni the clwlty wodd bo•n *illlng IO pty lh• iitms on th* ¢>p*n
market
T•&de and ¢th•f deb￿% are i•¢¢q•bsod •t th• Mttl•m•nl 4ffl¢¥Jni du• •ny ty•d• dlxount oll*i•d.
Pr•p4yments ai* tAlu*d ai th• amount pl•￿•d Th•1 of any tiath d+scryJnts du•.
C45h •t •nd In Iwftd
Cash ai bthhk Ind ca¥h ir* h￿d In£￿deS <&sh and Short ièiffl hlllthty I14￿ld lfiN*itments wlth & short
m•luilfy ol ihio* m¢nihs Of 1¢$$ Itom ih¢ dil¢ ol Kqulskllon 01 I￿enIng ot th* dtposll oi
account. Cash balarKts eM<kMk any funds hld on behall of swvi(• Iis•i&
Ciedit015 4nd prov151onJ •ie iecogn15ed *hoYt ihe charlty h45 i pre5eni 0￿•01160￿ resUl￿fig Irom a
p•sl •w*ni ih4t **ll pobabfy re$￿11 in th• Ifanslèi 01 lundi to a thlid party and th• un4>uni due to
settle the obltyatsoo cafi be me*sui*d oi estirrwted i•liably. Cieditws •r*d piowwns ale Trowmallv
iecognistd at ihéii Se1￿•m￿Al amotsftt aftei any trade &¥ounts due.
•) FlTh•fv¢lAI lftsiNm•fits
Tht (havity onty has finAncl•l ass¢ts and &abihb•s ol a knnd that qualify as basic finaYKlal
Instruments. 145K finan¢i•l Iostiumenls Initrally rKognised al lraft54ctl￿ and sUbseq￿entlY
IM4SUf*d at theif Mtil¢meni value *Tih the excep1￿ft ol bank loans tAthKh wbstquonity m*astsied
41 4mDrtlsod cos1 uslng th* ￿￿(¢1￿ mteiest method,
p> Penslyffii
Payments ¢0 doh•d conliibuljon r•tsrwn•Dt bqn•frt •wo chwg•d a5 In •xp•nge a5 th•y loll
55
Overview
Science
& Education
Financial raviaw
& Govornanca
Advocacy

o•si C4A¢ei IM UN￿4
No*5 *1 th•
orth•
•nd•d JI hI￿￿h
Z kn¢om• Irwi •nd l•w
202S
T•tsl Vftrmlrictsd Restrlckd
2024
Totsl
UTri*ityicl•d Resiikted
DoTrations arbd g•fts
Legacios iec•i¥•ble
1.088.950
189,155
16.795
.018,950 1.106.425
419,155
521.407
16.7•5
16.021
11,118 1,127.543
32 1.407
16.027
1.9•4.•00 1.443.a59
21.111 1.461.977
J ¢hwi￿bI* aciMU••
2025
T•tyl UnF•slilcltd A•slikltd
2024
Totsl
UTri•strlci•d R•strKt•d
2,485
19.829
S•k ol Apw•l
19,129
12.314
Z2.314
4 Inv•slm•nts
1025
Totsl Uniestrkt•d A•51rlcl
2024
Totsl
UThi•strlded R•stri(t•d
81.•SJ
Jl,•5J
72.647
72.647
•i.•sJ
11.•SJ
72.647
72.647
56
Overview
Science
& Education
Financial raviaw
& Govornanca
Advocacy

P*A¢J fir*rKMI
ortht
c¢*￿ ol
Ilew¢¢li
ONtlopmern
1024
Tot41
lunds
COU* X25 T￿1
•ff Costs (P40* n
746.1
JJ.41)9
191.749
243.240
149.3dJ
128.101
1.020J121
276W9
5.?J5
iQ.140
792•0
1•.699
1•.645
2>.249
611.342
54JI51
5.146
io.iis
29.fjlj
J4.J81
fees
Js
10.140
Iilin &
59.752
16.511
WJwiiglMJns Aryl
10.181
5.228
I69￿80
492
2.100
6AOO
12.)56
199J12
1.911
9.75)
169
16
1.159
1S,49?
Vtywwj Propk'4 It•￿￿¢•
i.J)o
54.968
6.115
24,991
514
Sj￿51
2.412
2A*41
JJ40
pi*l(vm lees
51dll th*llaiy
If•4d. •CCtyhmod#i¢h •NI
wran¢e
)J.5•1
33.581
iJM09
>•.)97
iJ,609
iJ.100
Y.461
11.611
421
2.317
S3,>J5
11.962
19.54J
5ur¥lii
Teltplv
Dtpieriwi
1.951
572
1.951
5T2
617
617
49
Nlii lrts
1.440
4.jis
647
?,592
1.511
21.640
4f>9
J9.562
J65.916
SX*58
552.179
5t*,4J2
1.119
391,J02
xI.919 1 1 160011
10.9191
Jyi
57)
Ikn loui eyndiiuie 11*91109 V••$ w¥eyrKi*d 12024 1 I* J6.429y ￿ 12,15911014 112J.5•n￿5 lo41￿10￿.
Co4 01
RewAI( li
X124
150.360
l i.yji
l I9￿0
16.1S1
25JA54
J.Y98
129,43
61J.M?
J4,051
5,146
10,135
79.971
J4.J81
*)qr•mt ewThJitw•
(.on*iJiiAnrn f*e%
%*ichdndise 4wd Maieii4,
5,146
10.315
6.9J4
?.JJ•
j4.jll
J.584
Conlr*trNr a•¥J
5ub4iipl￿l1s a￿1 Inernlwshyi
bo
1,041
i.mo
ii,Jy
19y J12
5.106
Pthttsilmellt
J21
i.jjo
9A
1.911
i.jio
14,
6.115
24.991
514
5J,658
2..iip
2.647
3.240
49
t*JtKJi w)iii lees
6.lJS
16.491
5J4
5J.658
9)2
).ioi
J.9$9
knsutdme
Ii*b¥ie arwl IT
2.647
J.240
haiges
4•
*<Lour*4wKV fe*1
1.152
1.440
2.$92
lJ6fiJl
iiihi)
XW),lfyi
ZJ4,191
10.149 1,160,011
110,1491
TO￿ 2024
?J6ffjJi
176.J04
510.119
2J6J15T
57
Overview
Science
& Education
Advocacy
Financial raviaw
& Govornanca

lrnast CaKqr UK Urnl•d
Nol*s th th• Stskffl•nts
Forth •Nl•d JI I￿r(h 2025
6 N•t lrtomlw r•w¥rt•i lor th• y•4r
Thls Is ststod after charyk¥ I ¢￿Irt1￿.
1025
1024
sn
Audlior5' iemun•rntb)n fvxcludlng VATI..
Audtt
6.000
6.000
T Amprnts of staff costs. lThit•• rnfi¥Jn•Ath)n and •xp•ftMs. and th• cost of kny rnanag•ThrA
p•ThonA•I
Staff costs as lollm..
2025
2024
Salanes and *ag•s
So(thl s•<uilly cosis
Empty)￿￿5 conlilbutlon io d•flMd sch•m*s
Fr••Tranc• staffs
165,028
13,57)
29.194
53.026
579,127
44,300
20,010
29.945
1.020.811
67 1.382
Th• number Ol•Mpb￿QS whDs• aTrwal rnftwJMratb)n Ihan 160.OIXI lolki*￿.
20ZS
2124
£80.001-£90,0
Tho ithal empby•• berbtltts hKludlno pensknn and natkjral Insurnnc• con1d￿t￿)￿S ol th• knv
manaym*nt p*isonMI **ie 197.760 12024.. £79.5961.
Tho chalky tIUSl•os TA•1• N¥1 or 01￿1 from •mpk>yThnt *lth thi charlty
ith• y*4r 12024.. £ n¢D. No chatmy itus11• rK•ké•d paym•thi foi pmf•ssloNII oi oih•i ￿TrIC*S stsppll
lo ihe (￿lIty(2024.. £nlD.
Tffustoès. 0xpon￿5 IKIMl• iho payffleni or rnlffllMn•nxni of t14￿1 and suhlstsTrc• cos15 toullkn
£217 12024,, 12801 r•laiing Io all•NIa￿• al m••tings ol th• INSI￿$.
8 ￿Mbl
Th• I￿￿9* M￿nIhI¥ numb•r al •mplty••s duriw y•ai was..
2015
No.
2024
Manaoemonl 4NI admln151r41fv)n
Fundralslrrtj
Cimpalgns. SclÈKe Edvuibn
20.9
58
Overview
Science
& Education
Financial raviaw
& Govornanca
Advocacy

lrnast CaKqr UK Urnl•d
Nol*s th th• Stskffl•nts
Forth •Nl•d JI I￿r(h 2025
g R•kn*d p•rw
Thore ar• no Trlated party transactknTrs to dls(th>se for 202S Q024: nono).
TheTr no d¢n*ibons Irom r*lated part*s whkh 4r• ouisxh t￿ norm41 ol buslmsi and fio
v*strlckd donaiions IrDm related partles.
10 Tuatknn
Th• c￿111•1￿* Com￿ry 15 •x•mpi Imm cowaik*n lax as al Is Incom IS chaiiiibh afvj h appll•d lor
charttable wrpDS*S.
I l T*r8lbl• flx•d 4$1•ts
Equlpm*nt
Total
At ihe of ith•
Addbtktrns In
Dlspou15 In y*•i
2,755
2.7$5
At ih• •nd ol ih• y•ai
2.IS5
2.155
At th• slail ol ih• y•ar
Charge lor tht ￿ar
Ellmhvi*d on dhp)sal
572
sn
At th• end ol lh• y*ar
572
5T2
Ai th• •r4 01 y4•f
2.18J
2.183
At ih• of ih y•ar
All ol ih abo¥• 4rn us•d lor thar*4bl& PUfPOS•I.
li Sknck
2025
2024
ol Apparnl
29.14J
29.845
13 D•bw
2025
2024
Mon1è5 07￿1
her dèbioffs
Pr•piyn*nis and i(cn￿d Incom•
17.204
9.546
164,332
20.782
395.544
416,326
191,082
59
Overview
Science
& Education
Financial raviaw
& Govornanca
Advocacy

lrnast CaKqr UK Urnl•d
Nol*s th th• Stskffl•nts
Forth •Nl•d JI I￿r(h 2025
14 CThdlkbrs: tslllry dw f*lthkn on• ￿ar
2025
2024
Ti*d• cr*diro
Taxatk>n and soclal s￿1￿¥
CAnts payablè
h•r crndllOIS
A(cNa
101,026
2Q,401
12,97S
139.514
3,345
9.136
33.091
5,120
11.717
156.9S4
18S,J71
15 Crnllknrs: afflounts f•lllw •ft•r or•J
2025
2024
GRnts payabh Inoi• 16>
121,5•6
126.424
121.596
126.424
16 Grnnls g•y•b
Gftnts payabl• IncbJd•d In t￿ IIDaKIAI su*m•ni% as lolk)ws:
2025
2024
GAnts pl￿bI• li InC￿d￿d *41hlft:
Curf•nl ithbilliltg
Non-curw•ni liabllttl•s
JJ,091
IZl.5
139.514
126.424
154.677
26S.938
lovemenis In ih• yur..
latsnc• al lthe Ixglnnlng ol oh• y•ar
R•h4s*d from prevlous p•rK)ds
AffKthUDi accrued In yeai
165,934
192.197
Q12.148) 1125.5321
101,547
199,273
154.677
265.938
17 P•Mknn Kh•m•
Tho chafity operatos a deflmd conlrSbutknn pènsk>n scheme for all quallfyin9 ompknyoos. The asuts 01
th• schm¢ ar* h•ld s•parat•try liom thos• ol tth• (￿rIlY lffi an Ind•wNl•nily adminhl*rod lund.
The (￿r9e to pmltt oi loss In of d•fIn￿ contrltwtlon sch•m•s VAS £29.194 (2024 - £20.010).
60
Overview
Science
& Education
Advocacy
Financial raviaw
& Govornanca

lrnast CaKqr UK Urnl•d
Nol*s th th• Stskffl•nts
Forth •Nl•d JI I￿r(h 2025
CeTheral
unreslrKted O*siqNt•d R•stdcthd Tolal fmfids
Tawlbk Ifxod ass•ts
Nti cutrnni assèis
L•n4 i•rm Mibllitks
2.183
1.719.J21
1121.586)
2.183
46.166 2.452,548
(121.586)
686.461
Il•t a*Mii li th• •NI ol th• y•ar
1.599.918
6.461
46.766 2,333,145
19 In fvAd•
Incomlwj
At start r•sources &
ofth r4ar
•alvbs
ty0*
souTces &
At lh• •rA
Tiin$l•￿ ￿ th• r4ar
R•strknd lurds:
ploph •dtscatk+nal r•swr¢•
Ir•isi c4K*w lty m*n r*sourc•
47.570
1.355
Q,159)
1,355
TotAI rnstr*¢•d lunds
48.925
(z,Is*
46.766
D•iloMi•d l¥ndi',
ComnNnk•llon
ICUK br•ndlng fwI•*
Moblli5allon
IOJK Podcast
•CiJK Corpor41• film
A(c•sslblllty Audll
websi￿ updates
Educalb)n
A•ducè your Rlsk lffipaa swdy
0.200
15.0
17.J65
10.OCKJ
6.SLK)
10.0
(7,566
15.1)(Kl
12,187
4,399
6,50D
15,17
15.601
(i o.o¢)
S0.ONJ
50,IX
Dfrtrtktrpmeni ol 5￿pp•1 clubs
D*trtlopment ol
In•Tchandls•iappar•l
Publk Aflal
parllam•NN 04rtrNch
A•sUrth and Erw•n*n¢
SCI*￿• Grani 8udgei
ICiJK PIt￿ntIOn Conhr*K• 2025
¢r*ach Prograrnmo
Fwndatlon Award coachln9
Scle￿+ Foundaik•n Ax
S**d Awai¢ls
Oryanlsitknn dmlowmftl
D•p•nmenul L•gil f*•s
23.4
(5,OS5
11,345
24,J17
Q4.Jin
5.000
172.380
36.0
37.0(M)
1169.88
19,216)
2,500
26.784
37,IxvJ
I,50Q
Jso,000
147.620
2.500
150.Ot)O
50.0(K)
2ty).0
97.620
12.992
11.992
Totsl d•ilgnal•d tund%
712.782
Q36.8131
210,492
686.461
G•Mrnl fvrnls
1.369,139 2.099.161 (1.657.8961 o i 0.492) 1,599,918
Totsl uM•%trktad f¥ndi
2.081.921 2.099.167 <1.891.70•
2286.J79
Totsl fvnds
2,130.846 2,099,167 <1,ts6.afj•
I,J33,145
61
Overview
Science
& Education
Financial raviaw
& Govornanca
Advocacy

lrnast CaKqr UK Urnl•d
Nol*s th th• Stskffl•nts
Forth •Nl•d JI I￿r(h 2025
19. Mov4m•nls In l¥ras Ifofilbmmd)
ol Y•itrfa•d
Income, *thkh Is ￿C•￿ed loi swcllk pJrp05•S. a5 - for *xamph - gran15 and donatk>Tr5 - b •<couni•d
for as résir*led funds. wlth expendltuTr usuawy Altrlbuled ob*r a 5peclfk perlod ol ilme. Thè chaTIty
manag*s r*sii*ied lunds ¢ar*lulty. k••p 1X￿￿d11ufft und•r r*9utsi r*vlew, INI alm ty mt•i ih•
spKlfbEd purpos•5.
PUry>r•￿$ of d•slpnat•d
D*sfvJni¢ed ar• il* fufvds whlch bmn s•1 al￿• out ol UfftrnSirlci•d funds by th• tNs*•s
Incoml
l Aprll w•sourcos &
2023
galfts
$4yJrcts &
k•5S•S
JI Ma￿h
2024
Tiansl•rs
Youty éducatk)nal r•sour<•
Brnasl caKer men TewuT(•
Ilsphenols ros•arch Pfole(t
mo4*m•nt
G•rnial scknn<• rns•aich
47.570
1.567
19.802
2.450
80.000
47.570
1.355
11,J3o)
(19,802)
(2.4S0)
11 ¢J).000)
20.000
Totsl rnstrk¢•d fvnds
151.389
21.118
1123.5821
48.925
fundi:
Scl*K* Grani Bydg•l
C•ftv•ish)n ol Onlln•
HRT kliniblk bflof
lTrasl Fo•dinq rosour(•
ICUK Pw*v•ntlon Conhf•K4 2025
Ouirnach Piogramm•
5clefi(e Foundallon Awa
S••d Awirds
R•duce youi Rlsk lfflpait sknmly
D*vekbpmeni ol sup￿1 (l￿bi
DI￿1¢p￿t￿l ol
D?1￿￿•d parllaminis oulrtath
Economlc anafysls iool
BCIIK brandlng
Mobilis•ilon
ICIJK Podcast
ICIIK Corp)Trle fllm
cesslbllbty Audli
W•bs1* updat+s
420000
147.6201
172380
11 o,0¢)
(9,0001
15,000)
9.0
5,0
36.000
37.000
200.(
50.0Tr)
50.QIXI
23.4Th)
24.317
36.1)00
3 T,1)00
200.000
97,620
50,000
23,400
24.317
s.ooo
47.620
15,000)
(11.81)0)
20.QIXI
8.200
1S.QOO
17.J6S
i 0.000
6.500
i o,ooo
20.365
io.¢
6.5ts)
10.0
(J,0￿>
T•tal d*ihJMi•d lurds
444.0
512.582
12d3,8¢Y)I
712,782
1.157.844 1.003.924
1792,6291
1.369.139
Totsl unrnstwti*d
1.601.8M I.516.$06 11.036,429)
2.081,921
Total fyNIs
.753.233 1.537.624 11,160,011>
2.130,846
62
Overview
Science
& Education
Financial raviaw
& Govornanca
Advocacy

lrnast CaKqr UK Urnl•d
Nol*s th th• Stskffl•nts
Forth •Nl•d JI I￿r(h 2025
20 A•￿ttl1￿¢￿￿ ￿ n•1 thc•m• l tyxp•rAlts•rn) lo n•1 ush fTVm •p•rnilw Kltr4tt1•1
2025
2024
M•t IKom* l (•xp•ndltsrn) for th• rnportthg p•thd
s p•r th• sut•m•ni ol Ilnarlcknl •Clh7*1•$1
D•pre¢4ibn char9eS
Dlwfidonds. knl*ftsi and rnnt Irom 1Th￿SIMIn
(Loss1,,profrt on t￿ ol llxed assets
OKr•as•)Idecr*a5• In stocks
Ortroas•)Ide¢reaso In deb￿r5
IrKrnase i¢d*cwasel hb credltyis
202,299
317,613
572
(ai,953) 172.647)
Q9,8451
Q25,244) 11 52.336)
133,255)
94,257
1167,424)
246,887
21 Amtysts ol ash and •quh•knty
Aijl
Al l Awll
2024
oih•r
chatyes
Cash Ih)*
2025
Cash In hand
2,251,559
188.226)
1,163,333
Totsl ush •fyl railb •ytrrtl•n
2.251.559
188,226)
2,16J,J3J
21 I￿1 ol th• cknAty
Th• ch4rlty Is a compary lIm￿ed guaAnt** and sharn caplt41. Tht ￿bIlIty el oach momb•r
In •¥•ni ol wltsdlng up Is IlmK•d to I l.
63
Overview
Science
& Education
Financial raviaw
& Govornanca
Advocacy

IMPACT AND
ACCOUNTS
REPORT FY24/25
Thank you.
breast
cancer
breast
cancer uk.
Preventron saves lives